(1) Background: Our understanding of and treatment for multiple myeloma (MM) has advanced significantly, and new pharmacological treatments have promising benefits but high price tags. This study analyzes prescription patterns and pharmaceutical expenditure for MM treatments in Catalonia’s public healthcare system over eight years. (2) Methods: A retrospective observational study examined MM treatment data from 2015 to 2022 in Catalonia, using healthcare registries from the Catalan Health Service to collect information on patients, medicines used, and treatment costs. (3) Results: A total of 4556 MM patients received treatment, with a rising trend in the number of treated patients each year from 902 in 2015 to 1899 in 2022. The mean age was 68.9 years, and patients were almost evenly distributed by gender (51.5% male). Most patients were treated with bortezomib (3338 patients), lenalidomide (2952), and/or daratumumab (1093). Most drugs showed increased utilization annually, most significantly for lenalidomide and daratumumab. The total pharmacological treatment cost throughout the entire study period was EUR 321,811,249, with lenalidomide leading with the highest total cost (EUR 157,236,784), and daratumumab exhibiting the highest increase in annual expenditure. (5) Conclusions: The study reveals a progressive increase in the number of MM patients treated and rising pharmaceutical costs. Lenalidomide and daratumumab incurred the highest costs. The findings highlight MM treatment’s economic impact and the need to monitor prescription patterns and expenditures to optimize healthcare resources and decision making. Understanding these trends can guide resource allocation effectively.
(1) 背景：我们对多发性骨髓瘤（MM）的认识和治疗已取得显著进展，新型药物治疗虽前景广阔但价格高昂。本研究分析了加泰罗尼亚公共医疗系统八年间MM治疗的处方模式与药品支出情况。(2) 方法：通过一项回顾性观察研究，利用加泰罗尼亚卫生服务机构的医疗登记数据，收集2015年至2022年间MM患者的治疗信息、使用药物及治疗费用。(3) 结果：共有4556例MM患者接受治疗，年治疗患者数呈上升趋势，从2015年的902例增至2022年的1899例。患者平均年龄68.9岁，性别分布基本均衡（男性占51.5%）。大多数患者接受了硼替佐米（3338例）、来那度胺（2952例）和/或达雷妥尤单抗（1093例）治疗。多数药物使用量逐年增加，以来那度胺和达雷妥尤单抗最为显著。研究期间药物治疗总费用达321,811,249欧元，其中来那度胺总费用最高（157,236,784欧元），达雷妥尤单抗的年支出增幅最大。(5) 结论：研究表明MM治疗患者数量持续增长，药品费用不断上升，以来那度胺和达雷妥尤单抗的治疗成本最高。这些发现凸显了MM治疗的经济影响，提示需监测处方模式与支出情况，以优化医疗资源配置和决策制定。理解这些趋势有助于有效指导资源分配。
肿瘤(癌症)患者之家